Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
Crossref DOI link: https://doi.org/10.1007/s00262-014-1547-6
Published Online: 2014-04-27
Published Print: 2014-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Smith, David A.
Conkling, Paul
Richards, Donald A.
Nemunaitis, John J.
Boyd, Thomas E.
Mita, Alain C.
de La Bourdonnaye, Guillaume
Wages, David
Bexon, Alice S.
Text and Data Mining valid from 2014-04-27